"E’ una della maggiori Aziende sanitarie in Italia per dimensioni e complessità assistenziale. Il suo territorio comprende 46 comuni su un’area di 3.000 chilometri quadrati circa, per una popolazione di oltre 870.000 abitanti (poco meno di un quinto del totale dell’Emilia Romagna), con oltre il 23% di over 65nni, circa l’8% di ultraottantenni e l’11% di residenti stranieri."

During the past decade, Azienda Unità Sanitaria Locale conducted 17 clinical trials. In the 10-year time frame, 17 clinical trials started and 1 clinical trials were completed, i.e. on average, 5.9% percent of trials that started reached the finish line to date. In the past 5 years, 13 clinical trials started and 1 clinical trials were completed. i.e. 7.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Azienda Unità Sanitaria Locale" #1 sponsor was "Azienda Usl di Bologna" with 9 trials, followed by "Bayer" with 4 trials sponsored, "Takeda" with 2 trials sponsored, "Fondazione Poliambulanza Istituto Ospedaliero" with 1 trials sponsored and "Foundation IRCCS San Matteo Hospital" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Azienda Unità Sanitaria Locale" #1 collaborator was "Azienda Usl di Bologna" with 2 trials as a collaborator, "ASST Cremona" with 1 trials as a collaborator, "ASST Papà Giovanni XXIII Bergamo" with 1 trials as a collaborator, "AUSL Romagna Rimini" with 1 trials as a collaborator and "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)" with 1 trials as a collaborator. Other collaborators include 51 different institutions and companies that were collaborators in the rest 61 trials.

According to Clinical.Site data, the most researched conditions in "Azienda Unità Sanitaria Locale" are "Acute Coronary Syndrome" (1 trials), "Acute Non-cardioembolic Ischemic Stroke" (1 trials), "Atrial Fibrillation" (1 trials), "Biliary Tract Diseases" (1 trials) and "COVID-19" (1 trials). Many other conditions were trialed in "Azienda Unità Sanitaria Locale" in a lesser frequency.

Most popular intervention types in "Azienda Unità Sanitaria Locale" are "Drug" (6 trials), "Other" (5 trials), "Procedure" (5 trials), "Behavioral" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "24/7 Telephonic Palliative Care Service availability for the patients, their relatives, the EMS and Primary Care physicians taking care of them" (1 trials), "Apixaban" (1 trials), "Apixaban matching placebo" (1 trials), "Asundexian (BAY2433334)" (1 trials) and "Asundexian matching placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "Azienda Unità Sanitaria Locale" are 17 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Azienda Unità Sanitaria Locale". undefined are not yet recruiting, 10 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Azienda Unità Sanitaria Locale, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Azienda Unità Sanitaria Locale, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 6 trials that are defined as “Not Applicable".